PSTX vs. APLS, RNA, AKRO, PTCT, CRNX, RYTM, ACLX, DNLI, IMVT, and TWST
Should you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Akero Therapeutics (AKRO), PTC Therapeutics (PTCT), Crinetics Pharmaceuticals (CRNX), Rhythm Pharmaceuticals (RYTM), Arcellx (ACLX), Denali Therapeutics (DNLI), Immunovant (IMVT), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.
Poseida Therapeutics vs.
Poseida Therapeutics (NASDAQ:PSTX) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
Apellis Pharmaceuticals has a net margin of -34.97% compared to Poseida Therapeutics' net margin of -40.28%. Poseida Therapeutics' return on equity of -72.26% beat Apellis Pharmaceuticals' return on equity.
In the previous week, Apellis Pharmaceuticals had 21 more articles in the media than Poseida Therapeutics. MarketBeat recorded 21 mentions for Apellis Pharmaceuticals and 0 mentions for Poseida Therapeutics. Apellis Pharmaceuticals' average media sentiment score of 0.64 beat Poseida Therapeutics' score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.
Poseida Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Poseida Therapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 0.00%. Apellis Pharmaceuticals has a consensus price target of $46.71, suggesting a potential upside of 62.29%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Poseida Therapeutics.
Poseida Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
46.9% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 2.9% of Poseida Therapeutics shares are owned by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Apellis Pharmaceuticals received 304 more outperform votes than Poseida Therapeutics when rated by MarketBeat users. Likewise, 67.19% of users gave Apellis Pharmaceuticals an outperform vote while only 63.49% of users gave Poseida Therapeutics an outperform vote.
Summary
Apellis Pharmaceuticals beats Poseida Therapeutics on 14 of the 19 factors compared between the two stocks.
Get Poseida Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poseida Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PSTX) was last updated on 2/5/2025 by MarketBeat.com Staff
